Products

TAVALISSE® (fostamatinib disodium hexahydrate) tablets

Rigel’s first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate), which is the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. ITP is a rare autoimmune disease where the body’s own immune system attacks and destroys platelets in the blood.